{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:19:48Z","timestamp":1791883188251,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.coph.2011.02.007","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T12:03:11Z","timestamp":1301918591000},"page":"59-67","source":"Crossref","is-referenced-by-count":331,"title":["The role of serotonin receptors in the action of atypical antipsychotic drugs"],"prefix":"10.1016","volume":"11","author":[{"given":"HY","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BW","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2011.02.007_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002130050018","article-title":"An atypical compound by any other name is still an atypical","volume":"148","author":"Meltzer","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: a review","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.coph.2011.02.007_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0447.1987.tb02754.x","article-title":"Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia","volume":"75","author":"Youssef","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.coph.2011.02.007_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.coph.2011.02.007_bib0025","first-page":"59","article-title":"Long-term effects of neuroleptic drugs on the neuroendocrine system","volume":"40","author":"Meltzer","year":"1985","journal-title":"Adv Biochem Psychopharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.coph.2011.02.007_bib0030","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0035","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","article-title":"Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine","volume":"34","author":"Hagger","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New Eng J Med"},{"key":"10.1016\/j.coph.2011.02.007_bib0050","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in Schizophrenia study","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0055","doi-asserted-by":"crossref","unstructured":"Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, et al., for the CATIE investigators and the Neurocognitive Working Group: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007, 64:633\u201347.","DOI":"10.1001\/archpsyc.64.6.633"},{"key":"10.1016\/j.coph.2011.02.007_bib0060_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0065_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.coph.2011.02.007_bib0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.coph.2011.02.007_bib0075","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.bmcl.2009.09.041","article-title":"Synthesis and binding affinity of potential atypical antipsychotics with the tetrahydroquinazolinone motif","volume":"19","author":"Carro","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2011.02.007_bib0080","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1517\/14656566.2010.506188","article-title":"Evaluation of the clinical efficacy of asenapine in schizophrenia","volume":"11","author":"Minassian","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coph.2011.02.007_bib0085","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1517\/14656566.2010.502889","article-title":"Iloperidone for schizophrenia","volume":"11","author":"Rado","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coph.2011.02.007_bib0090","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.coph.2011.02.007_bib0095","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.coph.2011.02.007_bib0100_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.coph.2011.02.007_bib0105","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","article-title":"Molecular targets for treating cognitive dysfunction in schizophrenia","volume":"33","author":"Gray","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.coph.2011.02.007_bib0110","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.coph.2011.02.007_bib0120_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-009-1772-4","article-title":"Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit","volume":"209","author":"Gozzi","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbr.2006.01.019","article-title":"The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm","volume":"169","author":"Abdul-Monim","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.coph.2011.02.007_bib0130_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","article-title":"The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment","volume":"213","author":"Meltzer","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0135_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s007020050144","article-title":"The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice","volume":"106","author":"Carlsson","year":"1999","journal-title":"J Neural Transm"},{"key":"10.1016\/j.coph.2011.02.007_bib0140","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1046\/j.1460-9568.1999.00858.x","article-title":"Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A site for PCP-induced locomotion in the rat","volume":"11","author":"Millan","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.coph.2011.02.007_bib0145","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl)carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0006-3223(97)00424-1","article-title":"Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907","volume":"44","author":"Wadenberg","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0155","article-title":"5-HT2a and 5-HT2c receptor antagonism enhances risperidone-induced dopamine (da) efflux in rat medial prefrontal cortex (mpfc) and diminishes it in the nucleus accumbens (NAC)","author":"Huang","year":"2005","journal-title":"Neurosci Abs"},{"key":"10.1016\/j.coph.2011.02.007_bib0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","article-title":"5HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner","volume":"947","author":"Liegeois","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.coph.2011.02.007_bib0165","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.coph.2011.02.007_bib0170","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0175","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-3565(25)12956-X","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.neuropharm.2004.04.020","article-title":"The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors","volume":"47","author":"Steward","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF01244654","article-title":"Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients","volume":"85","author":"Arora","year":"1991","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.coph.2011.02.007_bib0190_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archgenpsychiatry.2009.176","article-title":"Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia","volume":"67","author":"Rasmussen","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0195","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":"Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacol (Berl)"},{"key":"10.1016\/j.coph.2011.02.007_bib0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.npp.1301448","article-title":"CLozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine","volume":"33","author":"Elsworth","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0893-133X(94)00060-D","article-title":"Plasma clozapine levels and the treatment of l-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine","volume":"12","author":"Meltzer","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0210","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's Disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0215","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0220_1","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.coph.2011.02.007_bib0225_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sj.npp.1301098","article-title":"SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug","volume":"32","author":"McCreary","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2011.01.015","article-title":"Serotonergic regulation of neuronal excitability in the prefrontal cortex","author":"Andrade","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0235","doi-asserted-by":"crossref","first-page":"17194","DOI":"10.1074\/jbc.M801713200","article-title":"Activation of 5-HT2A\/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex","volume":"283","author":"Yuen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2011.02.007_bib0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0245","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","article-title":"The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia","volume":"49","author":"Sumiyoshi","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0250","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.pnpbp.2007.02.017","article-title":"Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia","volume":"31","author":"Sumiyoshi","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0255","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.euroneuro.2007.11.005","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors","volume":"18","author":"Hagiwara","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","article-title":"Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors","volume":"202","author":"Nagai","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0265","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","article-title":"Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study","volume":"355","author":"Newman-Tancredi","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.coph.2011.02.007_bib0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.105.087163","article-title":"Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain","volume":"315","author":"Assi\u00e9","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0280","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1017\/S146114571000009X","article-title":"Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors","volume":"13","author":"Bortolozzi","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0285","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2010.04.012","article-title":"Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801: Clz and MK-801 in KO1A mice","volume":"59","author":"Scorza","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0290","doi-asserted-by":"crossref","DOI":"10.1177\/0269881110388329","article-title":"Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone","author":"Frankle","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2009.08.019","article-title":"F15063, a potential antipsychotic with dopamine D(2)\/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum","volume":"620","author":"Bruins Slot","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0300","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","article-title":"Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors","volume":"260","author":"Roth","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0305","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0310","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.1016\/S0021-9258(17)32625-X","article-title":"Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands","volume":"269","author":"Barker","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2011.02.007_bib0315","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1074\/jbc.274.14.9472","article-title":"RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity","volume":"274","author":"Niswender","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2011.02.007_bib0320","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1523\/JNEUROSCI.22-24-10529.2002","article-title":"Modulation of serotonin 2C receptor editing by sustained changes in serotonergic neurotransmission","volume":"22","author":"Gurevich","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.coph.2011.02.007_bib0325","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0893-133X(00)00223-2","article-title":"RNA editing of the human serotonin 5-HT2C receptor. Alterations in suicide and implications for serotonergic pharmacotherapy","volume":"24","author":"Niswender","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0330","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","article-title":"Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens","volume":"24","author":"De Deurwaerdere","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2011.02.007_bib0335_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2011.01.025","article-title":"Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats","author":"Creed-Carson","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.coph.2011.02.007_bib0340","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.biopsych.2005.07.035","article-title":"Clozapine and haloperidol differentially alter the constituitive activity of central serotonin2c receptors in vivo","volume":"59","author":"Navailles","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1471-4159.1996.66010047.x","article-title":"Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor","volume":"66","author":"Kohen","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.coph.2011.02.007_bib0350","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.coph.2011.02.007_bib0355","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0026-895X(25)13616-X","article-title":"Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs","volume":"43","author":"Monsma","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0360","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","article-title":"Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors","volume":"268","author":"Roth","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0365","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0269881108095704","article-title":"Asenapine induces differential regional effects on serotonin receptor subtype","volume":"24","author":"Tarazi","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0370","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbr.2007.11.010","article-title":"The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801","volume":"188","author":"Pitsikas","year":"2010","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.coph.2011.02.007_bib0375","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145710000659","article-title":"Lu AE58054, a 5-HT(6) antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats","volume":"13","author":"Arnt","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0380","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2011.02.007_bib0385","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/FBP.0b013e3282f62d8c","article-title":"Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity","volume":"19","author":"Galici","year":"2008","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.coph.2011.02.007_bib0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biopsych.2006.12.011","article-title":"Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition","volume":"63","author":"Semenova","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.coph.2011.02.007_bib0395","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0091-3057(01)00744-4","article-title":"Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia","volume":"71","author":"Pouzet","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.coph.2011.02.007_bib0400","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.npp.1300626","article-title":"Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride","volume":"30","author":"Wagner","year":"2005","journal-title":"Neuropsychopharmacology"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489211000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489211000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:52:06Z","timestamp":1741103526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489211000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S1471489211000208"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2011.02.007","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}